Free Trial

Elevance Health (ELV) Stock Forecast & Price Target

$519.19
-2.22 (-0.43%)
(As of 05/28/2024 ET)

Elevance Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Consensus Price Target

$587.42
13.14% Upside
High Forecast$621.00
Average Forecast$587.42
Low Forecast$552.00
TypeCurrent Forecast
5/30/23 to 5/29/24
1 Month Ago
4/30/23 to 4/29/24
3 Months Ago
3/1/23 to 2/29/24
1 Year Ago
5/30/22 to 5/30/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$587.42$587.42$567.90$570.60
Forecasted Upside13.14% Upside15.85% Upside21.96% Upside21.23% Upside
Get Elevance Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ELV and its competitors with MarketBeat's FREE daily newsletter.

ELV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ELV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Elevance Health Stock vs. The Competition

TypeElevance HealthMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.70
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside13.14% Upside724.94% Upside10.85% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$575.00 ➝ $585.00+9.77%
4/19/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$574.00 ➝ $575.00+7.49%
4/19/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$585.00 ➝ $605.00+13.75%
4/19/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$580.00 ➝ $600.00+13.01%
4/19/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$557.00 ➝ $600.00+13.01%
4/19/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$584.00 ➝ $621.00+18.24%
4/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$602.00 ➝ $604.00+15.01%
4/10/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$580.00+13.45%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$569.00 ➝ $552.00+19.39%
10/19/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$585.00 ➝ $587.00+26.27%
7/24/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$564.00 ➝ $585.00+24.19%
7/20/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$555.00+19.82%
7/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
4/27/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade
4/21/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$565.00 ➝ $550.00+20.90%
4/20/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$571.00 ➝ $575.00+25.73%
1/26/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$580.00+17.03%
9/9/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$535.00 ➝ $575.00+17.50%
7/22/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$577.00+25.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:18 AM ET.

ELV Frequently Asked Questions

What is Elevance Health's stock forecast and purchase recommendation?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevance Health is $587.42, with a high forecast of $621.00 and a low forecast of $552.00. The consensus rating for Elevance Health stock is Moderate Buy based on the current 1 hold rating and 12 buy ratings for ELV. Learn more on ELV's analyst rating history.

Do Wall Street analysts like Elevance Health more than its competitors?

Analysts like Elevance Health more than other "medical" companies. The consensus rating score for Elevance Health is 2.92 while the average consensus rating score for "medical" companies is 2.70. Learn more on how ELV compares to other companies.

Does Elevance Health's stock price have much upside?

According to analysts, Elevance Health's stock has a predicted upside of 15.85% based on their 12-month stock forecasts.

What analysts cover Elevance Health?

Elevance Health has been rated by research analysts at Barclays, Cantor Fitzgerald, Jefferies Financial Group, Mizuho, Royal Bank of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.


Stock Forecasts and Research Tools

This page (NYSE:ELV) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners